TY - JOUR
T1 - Effects of an antihypertensive combination in japanese hypertensive outpatients based on the long-acting calcium channel blocker benidipine on vascular and renal events
T2 - A sub-analysis of the cope trial
AU - Combination Therapy of Hypertension to Prevent Cardiovascular Events (COPE) Trial Group
AU - Umemoto, Seiji
AU - Ogihara, Toshio
AU - Matsuzaki, Masunori
AU - Rakugi, Hiromi
AU - Shimada, Kazuyuki
AU - Hayashi, Koichi
AU - Makino, Hirofumi
AU - Ohashi, Yasuo
AU - Saruta, Takao
N1 - Funding Information:
The COPE trial was conducted as a collaborative research effort between Yamaguchi University and the sponsor KKC, Tokyo. The publication of this sub-analysis was finan-cially supported by KKC. KKC had no role in the design, data collection, performance, interpretation, or writing of this sub-analysis. We thank the collaborators and members of the COPE trial group. The COPE trial was supported by the Japanese Society of Hypertension Trial registration: http://clinicaltrials.gov (identifier NCT00135551) and http://www.umin.ac.jp/ctr/index-j.htm (UMIN000001152).
Publisher Copyright:
© 2020 Bentham Science Publishers.
PY - 2020
Y1 - 2020
N2 - Background: In the trial known as COPE (Combination Therapy of Hypertension to Prevent Cardiovascular Events), three benidipine (a Calcium Channel Blocker; CCB) regimens were compared. Hypertensive Japanese outpatients aged 40–85 years (n=3,293) who did not achieve the target blood pressure of <140/90 mmHg with benidipine 4 mg/day were treated with the diuretic thiazide (n=1,094) or a β-blocker (n=1,089) or an additional Angiotensin Receptor Blocker (ARB; n=1,110). A significantly higher incidence of hard cardiovascular composite endpoints and of fatal or non-fatal strokes was observed in the benidipine-β-blocker group compared to the benidipine-thiazide group. Objective and Methods: We further evaluated the treatment effects of the three benidipine-based regimens on vascular and renal events in a sub-analysis of the COPE patients. Results: A total of 10 vascular events (0.8 per 1,000 person-years) including one aortic dissection (0.1 per 1,000 person-years) and nine cases of peripheral artery disease (0.8 per 1,000 person-years) were documented, as was a total of seven renal events (0.6 per 1,000 person-years). No significant differences in vascular and renal events were revealed among the three treatment groups: vascular events, p=0.92; renal events, p=0.16, log-rank test. Conclusion: Blood pressure-lowering therapy with benidipine combined with an ARB, β-blocker, or thiazide was similarly effective in the prevention of vascular and renal events in hypertensive outpatients, although there are not enough events to compare the difference in the three treatment groups.
AB - Background: In the trial known as COPE (Combination Therapy of Hypertension to Prevent Cardiovascular Events), three benidipine (a Calcium Channel Blocker; CCB) regimens were compared. Hypertensive Japanese outpatients aged 40–85 years (n=3,293) who did not achieve the target blood pressure of <140/90 mmHg with benidipine 4 mg/day were treated with the diuretic thiazide (n=1,094) or a β-blocker (n=1,089) or an additional Angiotensin Receptor Blocker (ARB; n=1,110). A significantly higher incidence of hard cardiovascular composite endpoints and of fatal or non-fatal strokes was observed in the benidipine-β-blocker group compared to the benidipine-thiazide group. Objective and Methods: We further evaluated the treatment effects of the three benidipine-based regimens on vascular and renal events in a sub-analysis of the COPE patients. Results: A total of 10 vascular events (0.8 per 1,000 person-years) including one aortic dissection (0.1 per 1,000 person-years) and nine cases of peripheral artery disease (0.8 per 1,000 person-years) were documented, as was a total of seven renal events (0.6 per 1,000 person-years). No significant differences in vascular and renal events were revealed among the three treatment groups: vascular events, p=0.92; renal events, p=0.16, log-rank test. Conclusion: Blood pressure-lowering therapy with benidipine combined with an ARB, β-blocker, or thiazide was similarly effective in the prevention of vascular and renal events in hypertensive outpatients, although there are not enough events to compare the difference in the three treatment groups.
KW - Antihypertensive therapy
KW - Calcium channel blocker
KW - Combination therapy
KW - Randomized clinical trial
KW - Renal event
KW - Vascular event
UR - http://www.scopus.com/inward/record.url?scp=85096641853&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85096641853&partnerID=8YFLogxK
U2 - 10.2174/1573402116666200129130151
DO - 10.2174/1573402116666200129130151
M3 - Article
C2 - 31995012
AN - SCOPUS:85096641853
VL - 16
SP - 238
EP - 245
JO - Current Hypertension Reviews
JF - Current Hypertension Reviews
SN - 1573-4021
IS - 3
ER -